UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Mar

    28

    FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

    Mar

    26

    New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

    Mar

    25

    UCB at the 2022 AAD Annual Meeting: Our Commitment to Advancing Science in Dermatology

     

     

    Mar

    24

    North Carolina Academic Engagement Night - Investing in our Future through STEM

    At UCB, we are committed to accelerating scientific discoveries by supporting innovation ultimately leading to the discovery of new solutions to help people capture the moments that matter. Part of this commitment is a strong foundational support for STEM education in our communities to help inspire the next generation of scientists.

    Mar

    15

    Voices on Value: Building a Sustainable Healthcare System Together – Our U.S. Sustainable Access and Pricing Transparency Report

    Last year, UCB launched its Voices on Value blog series to foster a dialogue around how to make our health system better, stronger, and more accessible now and in the future. To advance this dialogue, UCB is releasing its first-ever U.S. Sustainable Access and Pricing Transparency Report, which underscores UCB’s commitment to an innovative, competitive, and value-based system. 

    Mar

    07

    UCB Completes Acquisition of Zogenix, Inc.